Compare CMG & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMG | ILMN |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4B | 37.0B |
| IPO Year | 2005 | 2000 |
| Metric | CMG | ILMN |
|---|---|---|
| Price | $27.45 | $269.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 35 | 21 |
| Target Price | $43.55 | ★ $241.05 |
| AVG Volume (30 Days) | ★ 17.6M | 2.5M |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.70 | ★ 170.87 |
| EPS | 0.55 | ★ 2.22 |
| Revenue | ★ $11,925,601,000.00 | $4,343,000,000.00 |
| Revenue This Year | $9.25 | $6.48 |
| Revenue Next Year | $10.83 | $6.46 |
| P/E Ratio | ★ $50.76 | $120.92 |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $27.82 | $94.00 |
| 52 Week High | $41.52 | $309.35 |
| Indicator | CMG | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 24.45 | 54.67 |
| Support Level | N/A | $254.00 |
| Resistance Level | $33.60 | $309.35 |
| Average True Range (ATR) | 1.06 | 15.36 |
| MACD | -0.23 | -2.32 |
| Stochastic Oscillator | 1.89 | 27.62 |
Chipotle is a leading fast-casual, Mexican-inspired restaurant chain, generating $11.9 billion in sales across 3,983 company-operated US locations, 104 international units primarily in Canada and Europe, and 14 licensed stores largely operated in the Middle East at the end of 2025. The firm's revenue is primarily driven by food and beverage sales at its company-owned restaurants, supplemented by delivery fees generated through its first-party digital channels. Chipotle emphasizes ingredients with no artificial flavors and utilizes an efficient, assembly line service model to serve mainly customizable burritos, bowls, salads, quesadillas, and tacos.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.